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Virtual toxicology 
Xenometrix Inc. 
Stress is on the minds of 
pharmaceutical companies these 
days. The stress they are worried 
about is not, however, that suffered 
by their chemists, working long 
hours to find that elusive next drug. 
Rather it is the stress responses of 
single cells, which Xenometrix Inc. 
(Boulder, Colorado) is using in a 
reductionist approach to roxicology. 
As pharmaceutical chemists 
amass huge collections of chemicals, 
they cannot hope to test t:hem all in 
animals. Using rows upon rows of 
animals would not be acceptable, 
either ethically or financially. 
To fish out the few ac,tive 
compounds, companies have resorted 
to assays that test the responses of 
cultured cells or purified proteins. 
But even when a compound appears 
to be active by this measure, it may 
still be unacceptably toxic. 
Xenometrix hopes to uncover these 
toxicities, by examining which of the 
candidate drugs alters the expression 
of genes that are induced by stress. 
From Ames to Ames II 
The first person to substitute single 
cells for animals in toxicology was 
Bruce Ames, of the University of 
California at Berkeley. In the 1960s 
Ames developed a strain of 
Salmonella ~&%~utiurn to test for the 
mutagenicity (and so carcinogenicity) 
of compounds. The strain carried a 
mutation in one of its hist:idine 
synthesis genes that could be 
effectively repaired by any one of 
several missense mutations. Ames 
exposed these bacteria to various 
chemicals, and found that the 
number of bacteria that were now 
able to make histidine was 
proportional to the ability of the 
chemicals to induce carcinogenic 
mutations in animal models. 
The Ames II assay, developed by 
Pauline Gee in Ames’ laboratory, is 
now part of the Xenometrix product 
line. Gee constructed six Salmonella 
strains, each of which can regain the 
ability to synthesize histidine only by 
one of six possible missense 
mutations. Two other strains, 
developed as part of the original 
Ames test, detect a one or two base 
pair frameshift. Mutagenic 
compounds vary in the types of 
mutations that they introduce, so the 
pattern of histidine synthesis in the 
test strains acts as a fingerprint for 
each compound. 
Stress alerts 
Detecting the mutagenic potential of 
compounds is a routine procedure in 
drug companies, but there is more to 
toxicity than mutagenesis. Chemicals 
can damage cells and organisms in 
many ways, and cells have, in turn, 
developed mechanisms to detect and 
counteract that damage. This is 
where the Xenometrix leap of faith 
comes in. “We’re looking at [the 
induction of] genes -the first 
response that cells have - and we 
think that is indicative of the 
metabolic response further on,” says 
Gee, who is now the Vice President 
for Research and Development at 
Xenometrix. 
Each Xenometrix assay uses a 
bank of inducible promoters, some of 
which are synthetic promoters with 
the active elements from more 
complex promoters. Each promoter 
and its associated reporter gene is 
inserted into an individual bacterial 
or human cell line. The read-out is 
the activity or presence of reporter 
gene products. 
A simplified list of the toxic 
effects detected by two of the 
Xenometrix assays is given in 
Table 1. The real results are, 
however, more complicated. Any 
given chemical may cause several 
types of damage, and genes typically 
respond to a complicated 
combination of signals, some of 
which have not been characterized. 
“The surprises are probably less than 
lo%,” says Gee, “but it’s those that 
you notice, and you spend 90% of 
your time on them.” One way of 
making sense of certain responses is 
to look at the kinetics of induction, 
in an attempt to determine which 
responses are primary and which 
follow the induction of other genes. 
But does the system work? 
Just as the Ames assay had to 
struggle for recognition as a measure 
of genotoxicity, stress gene induction 
must be validated as a good indicator 
of other toxicities. Most toxicologists 
are enthusiastic about the general 
approach, but have reservations 
about applying the methods. “I don’t 
think we know enough about what 
the read-out means,” says Richard 
Morimoto of Northwestern 
University. The threshold of damage 
that cells respond to is poorly 
characterized, and so the significance 
of the signal is hard to interpret. 
“These monitors may be a little too 
sensitive,” says Morimoto. 
Jeffrey Theiss, the Director of 
Molecular Toxicology at Parke- 
Davis, believes that more work is 
needed. “Is the signal reflective of a 
particular toxicity, or of adaptive 
Competition 
Xenometrix is not the only practitioner of 
molecular toxicology, but it does appear 
to be the most ambitious. Pharmaceutical 
companies use individual gene read-outs, 
but Theiss says that these are devised 
and used “on a case by case basis that 
is not very efficient”. 
Other companies have mapped out 
specific applications. Azur Environmental 
(Carlsbad, California) monitors 
environmental contamination using 
bioluminescent bacteria. The 
luminescence of the bacteria varies with 
their overall respiratory activity. In Vitro 
International (Irvine, California) uses 
protein matrices to mimic delicate eye 
tissue. And although Advanced Tissue 
Sciences (La Jolla, California) is primarily 
interested in developing artificial skin for 
grafting (the skin is grown on nylon 
scaffolds seeded with discarded 
foreskins), they also use the skin to test 
cosmetics for irritant activity. 
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Table 1 
The Xenometrix stress assays. 
Damage or cellular insult detected 
The bacterial stress assay detects: 
Examples of promoters or promoter elements used (incomplete list) 
Oxidative damage 
Heat shock 
DNA damage 
Heavy metals 
Loss of cell membrane integrity 
Peroxidase 
DnaK (chaperone, hsp70 homolog); clpB (ATP-dependent protease) 
Gyrase and topoisomerase (regulate supercoiling, and their promoters are regulated by supercoiling); 
DNA repair enzymes (ada [methyl transferase], nfo [endonuclease IV]) 
Mercury reductase 
MicF (promoter responds to osmotic conditions, as the gene product regulates the production of a 
membrane channel) 
The human stress assay detects: 
Oxidative damage 
Heat shock 
DNA damage 
Heavy metals 
Biotransformation 
Mitogenesis 
Inflammation 
Cell cycle arrest 
GST Ya and HMTIIA (glutathione S  transferase subunit and human metallothionein,,,; both promoters 
have antioxidant response elements); NFKB response element 
Hsp70 and grp78 (chaperonins) 
GADD153 and GADD45 (growth arrest and DNA damage proteins); p53 response element 
HMTIIA (human metallothionein,,,) 
GST Ya and CYPl  Al (glutathione S  transferase subunit and cytochrome P450; both promoters have 
a xenobiotic response element that binds the dioxinlaryl hydrocarbon receptor) 
Fos (through a serum response element); collagenase (through a TPA response element, activated by 
protein kinase C); NFKB response element 
NFKB response element 
p53 response element 
changes that protect the cell from 
toxicity down the road?” he asks. 
“We don’t really know that yet.” 
Gee agrees with these caveats, 
but feels that Xenometrix is 
responding adequately by building a 
database - a survey of the responses 
to drugs whose toxicities are known. 
“We have to decide at what point 
[the drug has] overwhelmed the 
cell,” she explains, “and we are 
working to decide what that cutoff 
might be.” 
To help interpret the mountain of 
data, Xenometrix is developing 
pattern recognition software. Based 
on the assay results of compounds 
with known toxicities, the computer 
designs rules for predicting likely 
toxicities of novel compounds. This 
eliminates the bias that could come 
from specific scientific hypotheses. 
Bacteria or human 
Xenometrix produces the stress gene 
assays in both human cultured cells 
and bacteria. The bacterial assays 
have several advantages over the 
human assays, including promoters 
that are sensitive to osmotic stress, an 
oxidative stress response that is better 
understood, and simplicity. To mimic 
some of the metabolic reactions that 
happen in humans, a liver 
homogenate is added to these assays, 
and a cell-wall mutation is used to 
increase permeability to drugs. 
The human assays use more 
complicated culture conditions, but 
they have the obvious advantage of 
being closer to the clinical situation, 
an advantage they also have over 
various animal assays. 
Applications 
Gee estimates that, by next year, 
-60% of Xenometrix’s business will 
come from pharmaceutical and 
biotechnology companies, with the 
remainder split between cosmetic, 
chemical and environmental 
companies. For pharmaceutical 
companies, explains Theiss, the 
assays can be used in one of two 
settings. “If you have a drug pretty 
far along in development and 
identify a toxicity,” he says, “with 
these systems you can understand 
why a toxicity is there.” Once the 
mechanism of toxicity is identified, 
researchers can try to rationally 
modify the drug to remove the 
toxicity while retaining the 
therapeutic properties. 
The second application comes 
earlier in drug development, when 
the number of lead compounds is 
being whittled down. The stakes 
here are higher, and the drug 
companies are correspondingly more 
cautious about implementing the 
new assays. “If we develop a high 
level of confidence, then we could 
test compounds early on,” says 
Theiss. But a false positive in a 
toxicity assay could result in a 
valuable lead being discarded. 
Theoretically, these assays could 
be used to replace either animal or 
human testing, but neither 
Xenometrix nor its customers feel 
that this is imminent. The assays 
can, however, reduce the number of 
compounds that need to be tested in 
animals, by first eliminating those 
that are obviously toxic. And by 
using more stress-related genes (a 
gene-discovery effort is now 
beginning) and more powerful 
interpretive software, the detection 
of stress seems set to become a 
central feature in drug discovery. 
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